386 related articles for article (PubMed ID: 14687992)
1. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
Colucci M; Simioni P; Piro D; Prandoni P; Pagnan A; Semeraro N
Haematologica; 2003 Dec; 88(12):1383-9. PubMed ID: 14687992
[TBL] [Abstract][Full Text] [Related]
2. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Gresele P; Momi S; Berrettini M; Nenci GG; Schwarz HP; Semeraro N; Colucci M
J Clin Invest; 1998 Feb; 101(3):667-76. PubMed ID: 9449701
[TBL] [Abstract][Full Text] [Related]
3. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322
[TBL] [Abstract][Full Text] [Related]
4. Hyperprothrombinaemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis.
Binetti BM; Rotunno C; Tripodi A; Asti D; Semeraro F; Semeraro N; Colucci M
Thromb Haemost; 2006 Apr; 95(4):606-11. PubMed ID: 16601829
[TBL] [Abstract][Full Text] [Related]
5. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
6. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
7. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
Von dem Borne PA; Bajzar L; Meijers JC; Nesheim ME; Bouma BN
J Clin Invest; 1997 May; 99(10):2323-7. PubMed ID: 9153272
[TBL] [Abstract][Full Text] [Related]
8. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
[TBL] [Abstract][Full Text] [Related]
9. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
Nielsen VG; Steenwyk BL; Gurley WQ
J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
[TBL] [Abstract][Full Text] [Related]
10. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Jan; 85(1):5-11. PubMed ID: 11204587
[TBL] [Abstract][Full Text] [Related]
11. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
Bajzar L; Nesheim ME; Tracy PB
Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
[TBL] [Abstract][Full Text] [Related]
12. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
Viveros ME; Cabiedes J; Reyes E; Cabral AR
Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
[TBL] [Abstract][Full Text] [Related]
13. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
Stasko J; Hudecek J; Kubisz P
Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
[TBL] [Abstract][Full Text] [Related]
14. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor--no evidence for a cofactor role of protein S.
de Fouw NJ; de Jong YF; Haverkate F; Bertina RM
Thromb Haemost; 1988 Oct; 60(2):328-33. PubMed ID: 2975409
[TBL] [Abstract][Full Text] [Related]
15. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
[TBL] [Abstract][Full Text] [Related]
16. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
19. Activated protein C accelerates clot lysis by virtue of its anticoagulant activity.
de Fouw NJ; van Tilburg NH; Haverkate F; Bertina RM
Blood Coagul Fibrinolysis; 1993 Apr; 4(2):201-10. PubMed ID: 8388739
[TBL] [Abstract][Full Text] [Related]
20. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden.
Bajzar L; Kalafatis M; Simioni P; Tracy PB
J Biol Chem; 1996 Sep; 271(38):22949-52. PubMed ID: 8798478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
